Failure to launch: white paper explores the role of inappropriate use of IP in blocking access to generic and biosimilar medicines

Related Posts

• White Paper: Anatomy of a failure to launch: A review of… 5 November 2020 Open
• Smart reform of EU pharma and IP legislation key to boosting… 28 June 2022 Generic and biosimilar medicines lower healthcare treatment costs dramatically and…
• A new medicines trade and health security agenda for the… 19 February 2021 In response to the European Commission Trade Communication published on…
• New report reveals need for pricing and reimbursement and… 1 March 2021